Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
20.4% (vs 3.0% placebo) is the treatment-policy estimand intention-to-treat, everyone counted regardless of adherence and is the primary result published in NEJM
This manifests as: Persistent fatigue and weakness Breathlessness, particularly on exertion Palpitations or rapid heartbeat Pale or jaundiced (yellowish) skin Glossitis (sore, red tongue) Neurological and psychiatric symptoms can be particularly concerning and may become irreversible if deficiency remains untreated for extended periods
JAMA 332 , 952953 (2024)
doi:10.1016/j.mad.2003.11.005 Huff T, Mller CS, Otto AM, Netzker R, Hannappel E
Shipping Policy Orders ship within 1-2 business days Free shipping on orders over $150 Standard shipping: $9.99 (orders under $75) Reduced shipping: $5.99 (orders $75$149.99) Discreet packaging on all orders
